<DOC>
	<DOCNO>NCT02324621</DOCNO>
	<brief_summary>This phase I trial study long-term side effect continuation oral ONC201 treat patient solid tumor spread place body previously benefit receive drug . Oral ONC201 may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Continuation Oral ONC201 Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate long-term safety tolerability ONC201 ( oral ONC201 ) administer orally patient advance cancer . SECONDARY OBJECTIVES : I . To characterize pharmacokinetics ONC201 . II . To assess serum biomarkers therapeutic response ONC201 . III . To assess preliminary antitumor activity ONC201 single agent advance solid tumor . OUTLINE : Patients receive oral ONC201 orally ( PO ) day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week .</detailed_description>
	<criteria>Patient complete participation one ONC201 protocol , show tumor progression study treatment , tolerate study drug without unacceptable toxicity Patient meet criterion withdrawal base protocol Patient willing comply protocol requirement procedure , keep schedule study visit Patient agree practice effective contraception entire study period unless documentation infertility exist Patient able understand willing sign inform consent form Patient receive concomitant standard and/or investigational anticancer therapy ; local palliative radiotherapy permissible upon discussion principal investigator Patient alcohol substance abuse , opinion investigator , would interfere compliance safety Patient condition laboratory abnormality , opinion investigator , would pose additional risk administer study drug patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>protocol specific</keyword>
</DOC>